2,670
Views
13
CrossRef citations to date
0
Altmetric
Research Papers

A targeted IL-15 fusion protein with potent anti-tumor activity

, , , , , , & show all
Pages 1415-1421 | Received 29 Apr 2015, Accepted 04 Jul 2015, Published online: 20 Aug 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Mohammad Rasoolian, Majid Kheirollahi & Seyed Younes Hosseini. (2019) MDA-7/interleukin 24 (IL-24) in tumor gene therapy: application of tumor penetrating/homing peptides for improvement of the effects. Expert Opinion on Biological Therapy 19:3, pages 211-223.
Read now
Yue Liu, Yanlan Wang, Jieyu Xing, Yumei Li, Jiayu Liu & Zhong Wang. (2018) A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities. Drug Design, Development and Therapy 12, pages 2645-2654.
Read now
Elena García-Martínez, Melody Smith, Aitziber Buqué, Fernando Aranda, Francisco Ayala de la Peña, Alejandra Ivars, Manuel Sanchez Cánovas, Ma Angeles Vicente Conesa, Jitka Fucikova, Radek Spisek, Laurence Zitvogel, Guido Kroemer & Lorenzo Galluzzi. (2018) Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. OncoImmunology 7:6.
Read now
Siqi Chen, Jing Li, Qing Li & Zhong Wang. (2016) Bispecific antibodies in cancer immunotherapy. Human Vaccines & Immunotherapeutics 12:10, pages 2491-2500.
Read now

Articles from other publishers (9)

Jihong Chen, Ziyou Shen, Xiaoling Jiang, Zhenzhen Huang, Chongbing Wu, Dongcheng Jiang & Liusong Yin. (2023) Preclinical evaluation of IAP0971, a novel immunocytokine that binds specifically to PD1 and fuses IL15/IL15R α complex . Antibody Therapeutics 6:1, pages 38-48.
Crossref
Yumei Li, Lingjun Wu, Yueying Liu, Siwen Ma, Biyi Huang, Xianjing Feng & Hui Wang. (2022) A novel multifunctional anti-PD-L1-CD16a-IL15 induces potent cancer cell killing in PD-L1-positive tumour cells. Translational Oncology 21, pages 101424.
Crossref
Patrick G. Holder, Shion A. Lim, Christine S. Huang, Preeti Sharma, Yavuz S. Dagdas, Beyza Bulutoglu & Jonathan T. Sockolosky. (2022) Engineering interferons and interleukins for cancer immunotherapy. Advanced Drug Delivery Reviews 182, pages 114112.
Crossref
Xiaohu Zheng, Yaqi Wu, Jiacheng Bi, Yingying Huang, Ying Cheng, Yangyang Li, Yuwei Wu, Guoshuai Cao & Zhigang Tian. (2022) The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy. Cellular & Molecular Immunology 19:2, pages 192-209.
Crossref
Huilin Yang, Rakeeb Kureshi & Jamie B. Spangler. 2019. Structural Immunology. Structural Immunology 1 19 .
Changhua Zhou, Jing Li, Limin Lin, Rui Shu, Bin Dong, Donglin Cao, Qing Li & Zhong Wang. (2018) A targeted transforming growth factor-beta (TGF-β) blocker, TTB, inhibits tumor growth and metastasis. Oncotarget 9:33, pages 23102-23113.
Crossref
Xiaoqiong Wu, Siqi Chen, Limin Lin, Jiayu Liu, Yanlan Wang, Yumei Li, Qing Li & Zhong Wang. (2018) A Single Domain–Based Anti-Her2 Antibody Has Potent Antitumor Activities. Translational Oncology 11:2, pages 366-373.
Crossref
Renee N. Donahue, Lauren M. Lepone, Italia Grenga, Caroline Jochems, Massimo Fantini, Ravi A. Madan, Christopher R. Heery, James L. Gulley & Jeffrey Schlom. (2017) Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody. Journal for ImmunoTherapy of Cancer 5:1.
Crossref
Jieyu Xing, Limin Lin, Jing Li, Jiayu Liu, Changhua Zhou, Haitao Pan, Rui Shu, Bin Dong, Donglin Cao, Qing Li & Zhong Wang. (2017) BiHC, a T-Cell–Engaging Bispecific Recombinant Antibody, Has Potent Cytotoxic Activity Against Her2 Tumor Cells. Translational Oncology 10:5, pages 780-785.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.